COVID-19 vaccination shown to protect people with blood cancer

by Ludwig Maximilian University of MunichStudy time chart, anti-spike IgG levels and IgG avidity in individuals with hematologic neoplasia and in healthy individuals at different time points afte

Updated on: April 12,2024 13

COVID-19 vaccination shown to protect people with blood cancer

by Ludwig Maximilian University of MunichStudy time chart, anti-spike IgG levels and IgG avidity in individuals with hematologic neoplasia and in healthy individuals at different time points afte

Updated on:April 12,2024 13

COVID-19 cytokine storms may prevent a durable immune response

by Rachel Leeson,Massachusetts General HospitalCredit: CC0 Public DomainShiv Pillai, MD, Ph.D., investigator in the Ragon Institute of MGH, MIT and Harvard and professor at Harvard Medical Schoo

Updated on: April 12,2024 11

COVID-19 cytokine storms may prevent a durable immune response

by Rachel Leeson,Massachusetts General HospitalCredit: CC0 Public DomainShiv Pillai, MD, Ph.D., investigator in the Ragon Institute of MGH, MIT and Harvard and professor at Harvard Medical Schoo

Updated on:April 12,2024 11

Antibodies elicited by COVID-19 vaccination effective against delta variant

by Tamara Bhandari,Washington University School of Medicine in St. LouisCherry Grimmett, a BJC HealthCare security officer, receives her first dose of the Pfizer COVID-19 vaccine in December 202

Updated on: April 12,2024 11

Antibodies elicited by COVID-19 vaccination effective against delta variant

by Tamara Bhandari,Washington University School of Medicine in St. LouisCherry Grimmett, a BJC HealthCare security officer, receives her first dose of the Pfizer COVID-19 vaccine in December 202

Updated on:April 12,2024 11

T-cell abnormalities in severe COVID-19 cases

by Kumamoto UniversityA major difference between mild and severe cases of COVID-19 may be the extreme activation of T cells as they react to the virus. In mild cases, T cell activation is slowed

Updated on: April 12,2024 10

T-cell abnormalities in severe COVID-19 cases

by Kumamoto UniversityA major difference between mild and severe cases of COVID-19 may be the extreme activation of T cells as they react to the virus. In mild cases, T cell activation is slowed

Updated on:April 12,2024 10

COVID-19 vaccine responses to be studied in people with immune deficits

by NIH/National Institute of Allergy and Infectious DiseasesZebra-print ribbon, a symbol for awareness of primary immunodeficiencies and other rare diseases. Credit: NIAIDA study assessing how pe

Updated on: April 12,2024 19

COVID-19 vaccine responses to be studied in people with immune deficits

by NIH/National Institute of Allergy and Infectious DiseasesZebra-print ribbon, a symbol for awareness of primary immunodeficiencies and other rare diseases. Credit: NIAIDA study assessing how pe

Updated on:April 12,2024 19

Does the COVID-19 cytokine storm exist?

by Radboud UniversityCredit: CC0 Public DomainInflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known

Updated on: April 12,2024 17

Does the COVID-19 cytokine storm exist?

by Radboud UniversityCredit: CC0 Public DomainInflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known

Updated on:April 12,2024 17

Loss of smell following COVID linked to a person's immune reaction to the infection

by Bob Yirka , Medical XpressCredit: Pixabay/CC0 Public DomainA team of researchers from Columbia University Irving Medical Center, the University of Pennsylvania, the National Institute of Alcohol Ab

Updated on: April 12,2024 17

Loss of smell following COVID linked to a person's immune reaction to the infection

by Bob Yirka , Medical XpressCredit: Pixabay/CC0 Public DomainA team of researchers from Columbia University Irving Medical Center, the University of Pennsylvania, the National Institute of Alcohol Ab

Updated on:April 12,2024 17

COVID vaccine induces robust T cell responses in blood cancer patients

by The Peter Doherty Institute for Infection and ImmunityGraphical abstract. Credit:Cell Reports Medicine(2023). DOI: 10.1016/j.xcrm.2023.101017Researchers have found that, despite being h

Updated on: April 12,2024 19

COVID vaccine induces robust T cell responses in blood cancer patients

by The Peter Doherty Institute for Infection and ImmunityGraphical abstract. Credit:Cell Reports Medicine(2023). DOI: 10.1016/j.xcrm.2023.101017Researchers have found that, despite being h

Updated on:April 12,2024 19

Effectiveness of COVID vaccines unclear for people with immune deficiencies—but they're safe and worthwhile

by Vanessa Bryant and Charlotte Slade,The ConversationCredit: AI-generated imageThe COVID vaccine rollout is underway in Australia, with people inphase 1bnow eligible to be vaccinate

Updated on: April 12,2024 18

Effectiveness of COVID vaccines unclear for people with immune deficiencies—but they're safe and worthwhile

by Vanessa Bryant and Charlotte Slade,The ConversationCredit: AI-generated imageThe COVID vaccine rollout is underway in Australia, with people inphase 1bnow eligible to be vaccinate

Updated on:April 12,2024 18

Are autoantibodies in COVID-19 less harmful than previously thought?

by Berlin Institute of Health in der Charité (BIH)3D model of an antibody. Credit: TokenzeroCritically ill COVID-19 patients often have antibodies in their blood that bind to the body's own struct

Updated on: April 12,2024 10

Are autoantibodies in COVID-19 less harmful than previously thought?

by Berlin Institute of Health in der Charité (BIH)3D model of an antibody. Credit: TokenzeroCritically ill COVID-19 patients often have antibodies in their blood that bind to the body's own struct

Updated on:April 12,2024 10

New COVID-19 strategy: Vaccinate potential superspreaders first

by Macquarie UniversityCredit: Pixabay/CC0 Public DomainWith thousands of scientists around the world racing to develop a vaccine for COVID-19, policy makers may need to decide who is at the fron

Updated on: April 12,2024 11

New COVID-19 strategy: Vaccinate potential superspreaders first

by Macquarie UniversityCredit: Pixabay/CC0 Public DomainWith thousands of scientists around the world racing to develop a vaccine for COVID-19, policy makers may need to decide who is at the fron

Updated on:April 12,2024 11

Antibody production in patients hospitalized with COVID-19

by Mary Ann Liebert, IncCredit: Mary Ann Liebert, Inc., publishersAntibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COV

Updated on: April 12,2024 20

Antibody production in patients hospitalized with COVID-19

by Mary Ann Liebert, IncCredit: Mary Ann Liebert, Inc., publishersAntibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COV

Updated on:April 12,2024 20